Recruiting

All-extremity Exercise During Breast Cancer Chemotherapy

Currently, there are 3.5 million breast cancer survivors in the United States and this number is expected to increase dramatically. The proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. Findings may have implications for cardiovascular disease prevention in this population.

ClinicalTrials.gov IDNCT04914663

PhaseNA

Enrollment68

SponsorUniversity of Florida

Age18 Years

SexFEMALE

I'm interested View official listing

Conditions studied

Breast Cancer

About this study

Interventions

Behavioral: Exercise training — Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.

Primary outcomes

Change in brachial artery FMD (12 weeks)
Change in global longitudinal strain (12 weeks)
Feasibility, tolerability and safety of exercise training during breast cancer chemotherapy (Monitored throughout the 12 weeks of intervention)

Eligibility information

Inclusion Criteria: * Active diagnosis of primary invasive non-metastatic breast cancer, stages I-III * Female * 18 to 85 years of age * Scheduled to initiate neoadjuvant or adjuvant chemotherapy (anthracycline, alkylating agent and/or taxane) * Absence of contraindications to exercise * Study clinician approval * Able to give consent * Informed consent obtained from the subject and documentation of subject agreement to comply with study-related process Exclusion Criteria: * Do not meet inclusion criteria * Receiving targeted therapies (CDK4/6 or PARP inhibitors) * Receiving radiation therapy concurrent with chemotherapy * Lymphedema stage ≥ 2 prior to study enrollment * Any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent) * Current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)

Study locations

Integrative Cardiovasculal Physiology Laboratory, University of Florida, Gainesville, Florida 32611 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.